Cargando…

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.

The aim of the present retrospective study was to assess long-term survival after cisplatin-based chemotherapy in 398 patients with advanced urothelial transitional cell carcinoma (TCC) treated at seven international oncological units. Various combinations of cisplatin, methotrexate, vinblastine (or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fosså, S. D., Sternberg, C., Scher, H. I., Theodore, C. H., Mead, B., Dearnaley, D., Roberts, J. T., Skovlund, E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074866/ https://www.ncbi.nlm.nih.gov/pubmed/8932351

Ejemplares similares

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
por: Polee, M B, et al.
Publicado: (2003)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
por: Koguchi, Dai, et al.
Publicado: (2022)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
por: Dearnaley, D P, et al.
Publicado: (2005)

Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling
por: Galsky, Matthew D, et al.
Publicado: (2023)

SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
por: Geldart, Thomas, et al.
Publicado: (2015)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study
por: Lee, Yong Seong, et al.
Publicado: (2023)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
por: Nassif, Elise F., et al.
Publicado: (2021)

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
por: Abida, Wassim, et al.
Publicado: (2016)

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
por: Kerioui, M., et al.
Publicado: (2021)

Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)
por: Choi, Y J, et al.
Publicado: (2015)

Nuclear morphology predicts cell survival to cisplatin chemotherapy
por: Kim, Chi-Ju, et al.
Publicado: (2023)

The continuing role of chemotherapy in the management of advanced urothelial cancer
por: Gómez De Liaño, Alfonso, et al.
Publicado: (2018)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial Carcinomas
por: Kakehi, Yoshiyuki, et al.
Publicado: (1998)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)

Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors
por: Fung, Chunkit, et al.
Publicado: (2018)

The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up
por: Bjerring, Anders W, et al.
Publicado: (2020)

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
por: Han, K S, et al.
Publicado: (2008)

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
por: del Muro, X García, et al.
Publicado: (2002)

Response of the Urothelial Carcinoma Cell Lines to Cisplatin
por: Holíčková, Andrea, et al.
Publicado: (2022)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
por: Houédé, N., et al.
Publicado: (2016)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
por: Green, J. A., et al.
Publicado: (1988)

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study
por: Omland, Lise H., et al.
Publicado: (2020)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.
por: Chi, K. H., et al.
Publicado: (1998)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sjmrrvumcg4i2c4t7uvajmb4o7